Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immuneering (IMRX)
NASDAQ:IMRX
Holding IMRX?
Track your performance easily
IMRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.00 - $8.89
Previous Close$2.04
Volume165.56K
Average Volume (3M)5.53M
Market Cap
$63.34M
Enterprise Value$16.93M
Total Cash (Recent Filing)$50.66M
Total Debt (Recent Filing)$4.24M
Price to Earnings (P/E)―
Beta2.18
Next Earnings
Mar 05, 2025EPS Estimate
-$0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding31,050,448
10 Day Avg. Volume407,797
30 Day Avg. Volume5,531,090
Standard Deviation0.43
R-Squared0.00214
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)1.10
Price to Sales (P/S)2910.98
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue881.57
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.29
Forecast
1Y Price Target
$14.25Price Target Upside598.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Immuneering News
PremiumCompany Announcements
Immuneering Corp. Reports Q3 Loss, Highlights Progress
PremiumMarket News
3 Penny Stocks to Watch Now, 9/18/24
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe recent announcement of Orphan Drug designation for IMM-1-104 in pancreatic cancer highlights its potential in treating challenging conditions.
Promising Efficacy DataInitial Phase 2a efficacy data from the first cohort of patients treated with IMM-1-104 in combination with chemotherapy are very promising, with an overall response rate of 40% and a Disease Control Rate of 80%.
Strong Financial PositionThe company has cash runway into 4Q25, providing a stable financial foundation for ongoing and future clinical developments.
Bears Say
Clinical Trial RepresentativenessPatient 1, who achieved a complete response, did not have a KRAS mutation, raising questions about how representative the result is.
Clinical Trial ResultsThe phase I dataset did not increase confidence that IMM-1-104 or its mechanism of action can drive clinically meaningful regressions.
Drug EfficacyThe dataset does not yet increase confidence that this drug or its mechanism of action can drive clinically meaningful regressions.
---
Ownership Overview
30.64% Insiders
6.45% Mutual Funds
1.62% Other Institutional Investors
57.64% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IMRX FAQ
What was Immuneering’s price range in the past 12 months?
Immuneering lowest stock price was $1.00 and its highest was $8.89 in the past 12 months.
What is Immuneering’s market cap?
Currently, no data Available
When is Immuneering’s upcoming earnings report date?
Immuneering’s upcoming earnings report date is Mar 05, 2025 which is in 105 days.
How were Immuneering’s earnings last quarter?
Immuneering released its earnings results on Nov 13, 2024. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.552 by $0.062.
Is Immuneering overvalued?
According to Wall Street analysts Immuneering’s price is currently Undervalued.
Does Immuneering pay dividends?
Immuneering does not currently pay dividends.
What is Immuneering’s EPS estimate?
Immuneering’s EPS estimate is -$0.46.
How many shares outstanding does Immuneering have?
Immuneering has 31,050,447 shares outstanding.
What happened to Immuneering’s price movement after its last earnings report?
Immuneering reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.552. Following the earnings report the stock price went up 13.45%.
Which hedge fund is a major shareholder of Immuneering?
Among the largest hedge funds holding Immuneering’s share is Perceptive Advisors LLC. It holds Immuneering’s shares valued at N/A.
---
Immuneering Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.25 (598.56% Upside)
$14.25 (598.56% Upside)
Blogger Sentiment
Bullish
IMRX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 681.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.57%
12-Months-Change
Fundamentals
Return on Equity
-71.81%
Trailing 12-Months
Asset Growth
-39.80%
Trailing 12-Months
Company Description
Immuneering
Immuneering Corpbiopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to leading pharmaceutical and biotechnology companies.
---
IMRX Stock 12 Month Forecast
Average Price Target
$14.25
▲(598.56% Upside)
Technical Analysis
Best Analysts Covering IMRX
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
-14.35%
reiterated a buy rating 2 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of -14.35% per trade.
---